Evidence map›Paper›PMID 40746600›Full record

ArticleFrontiers in oncology2025

Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pancreatic cancer.

Keisuke Miwa, Reina Kawasaki, Mototsugu Shimokawa, Taiga Otsuka, Toshimitsu Tanaka, Masaru Fukahori, Taro Shibuki, Junichi Nakazawa, Shiho Arima, Futa Koga and 21 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Keisuke MiwaMultidisciplinary Treatment Cancer Center, Kurume University Hospital, Fukuoka, Japan.
Reina KawasakiDivision of Integrative Medical Oncology, Saiseikai Kumamoto Hospital, Kumamoto, Japan.
Mototsugu ShimokawaClinical Research Institute, National Kyushu Cancer Center, Fukuoka, Japan.
Taiga OtsukaDepartment of Internal Medicine, Minato Medical Clinic, Fukuoka, Japan.
Toshimitsu TanakaMultidisciplinary Treatment Cancer Center, Kurume University Hospital, Fukuoka, Japan.
Masaru FukahoriMultidisciplinary Treatment Cancer Center, Kurume University Hospital, Fukuoka, Japan.
Taro ShibukiDepartment for the Promotion of Drug and Diagnostic Development, Division of Drug and Diagnostic Development Promotion, Translational Research Support Office, National Cancer Center Hospital East, Chiba, Japan.
Junichi NakazawaDepartment of Medical Oncology, Kagoshima City Hospital, Kagoshima, Japan.
Shiho ArimaDigestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Futa KogaDepartment of Hepatobiliary and Pancreatology, Saga Medical Center Koseikan, Saga, Japan.
Yujiro UedaDepartment of Hematology and Oncology, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan.
Yoshihito KubotsuDepartment of Internal Medicine, Karatsu Red Cross Hospital, Saga, Japan.
Hozumi ShimokawaDepartment of Hematology Oncology, Japan Community Healthcare Organization Kyushu Hospital, Fukuoka, Japan.
Shigeyuki TakeshitaDepartment of Gastroenterology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
Kazuo NishikawaDepartment of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan.
Azusa KomoriDepartment of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan.
Satoshi OtsuDepartment of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan.
Ayumu HosokawaDepartment of Clinical Oncology, University of Miyazaki Hospital, Miyazaki, Japan.
Tatsunori SakaiDepartment of Medical Oncology, NHO Kumamoto Medical Center, Kumamoto, Japan.
Hisanobu OdaDivision of Integrative Medical Oncology, Saiseikai Kumamoto Hospital, Kumamoto, Japan.
Machiko KawahiraDepartment of Gastroenterology, Kagoshima Kouseiren Hospital, Kagoshima, Japan.
Shuji AritaDepartment of Chemotherapy, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan.
Takuya HondaDepartment of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Hiroki TaguchiDepartment of Gastroenterology, Izumi General Medical Center, Kagoshima, Japan.
Kengo TsuneyoshiDepartment of Gastroenterology, Izumi General Medical Center, Kagoshima, Japan.
Toshihiro FujitaDepartment of Gastroenterology, Saiseikai Sendai Hospital, Kagoshima, Japan.
Takahiro SakaeDepartment of Gastroenterology, Saiseikai Sendai Hospital, Kagoshima, Japan.
Yasunori KawaguchiDepartment of Gastroenterology, Asakura Medical Association Hospital, Fukuoka, Japan.
Tsuyoshi ShirakawaClinical Hematology Oncology Treatment Study Group, Fukuoka, Japan.
Toshihiko MizutaDepartment of Internal Medicine, Fujikawa Hospital, Saga, Japan.
Kenji MitsugiDepartment of Medical Oncology, Sasebo Kyosai Hospital, Nagasaki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The significance of third-line chemotherapy (CTx) in unresectable pancreatic cancer (UPC) remains unclear. This study evaluated the therapeutic impact of third-line CTx after nanoliposomal irinotecan and fluorouracil combined with folinic acid (nal-IRI + 5-FU/LV) therapy as second-line CTx for UPC. Methods: Between June 2020 and May 2021, 104 patients who received nal-IRI + 5-FU/LV therapy as second-line CTx were retrospectively analyzed for post-discontinuation survival (PDS) and overall survival (OS). Comparisons were made between patients transitioning to third-line CTx and those receiving best supportive care (BSC), using a Cox proportional hazards model adjusted for patient background. Results: Of the cohort, 34 patients received third-line CTx, whereas 61 transitioned to BSC. The median OS from first-line CTx in the third-line CTx group was 18.0 months, with a median OS of 9.7 months from second-line CTx. Adjusted median PDS following second-line CTx was 6.5 months for the third-line CTx group compared to 2.3 months for the BSC group (adjusted hazard ratio 0.16; 95% confidence interval 0.08-0.32; P < 0.01). Conclusion: Third-line CTx should be actively considered for patients with UPC, as the approach may significantly extend survival in those who can tolerate the treatment.

Indexed as

best supportive carechemotherapynanoliposomal irinotecanpancreatic cancerthird-line treatment

Identifiers

PMID40746600
PMCPMC12310504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.